Portfolio > NovaBiotics Ltd

NovaBiotics Ltd is an Aberdeen-based anti-infectives company and was founded in 2004. Its unique technology has already demonstrated enhanced efficacy, safety and bioavailability over current and emerging competition as well as the potential for a fast-track route to market and revenue initially through its first application, a topical (brush on) treatment for fungal nail infections, Novexatin™/NP213.

Nail fungus provides a significant but very poorly met global market. This condition affects in order of 12% of the global population and has a total potential market value in excess of $5 bn. NovaBiotics has successfully completed preclinical development for Novexatin™ and will enter first-in-man clinical trials in 2009. NovaBiotics platform technology and pipeline has the potential to expand into other

anti-infective markets. In particular, life-threatening invasive fungal infections, hospital and community acquired Gram-positive & Gram-negative respiratory and dermal bacterial and polymicrobial infections (including those associated with cystic fibrosis).

Latest News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
3rd March 2017

Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
7th June 2016

NovaBiotics Wins Investment of the Year Award
5th February 2016

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12th August 2015

Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium
12th June 2015

Launch of the BEAM Alliance
9th June 2015

NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19th January 2015

NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014
7th October 2014

Showcases increasing investor interest in the global stem cell sector
22nd September 2014

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex®
16th September 2014

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London
18th August 2014

Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group
25th July 2014